Leishmaniavirus-Dependent Metastatic Leishmaniasis Is Prevented by Blocking IL-17A

PLoS Pathogens

Volumn 12, Issue 9, 2016, Pages

  Hartley, Mary Anne ^a   Bourreau, Eliane ^b   Rossi, Matteo ^a   Castiglioni, Patrik ^a   Eren, Remzi Onur ^a   Prevel, Florence ^a   Couppié, Pierre ^c   Hickerson, Suzanne M ^d   Launois, Pascal ^e   Beverley, Stephen M ^d   Ronet, Catherine ^a   Fasel, Nicolas ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b INSTITUT PASTEUR DE LA GUYANE   (French Guiana)

^c CENTRE HOSPITALIER DE CAYENNE   (French Guiana)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FRENCH GUIANA; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENCE; IMMUNOPHENOTYPING; LEISHMANIA GUYANENSIS; MALE; MOUSE; NONHUMAN; PARASITE ISOLATION; PARASITE LOAD; PARASITE VIRULENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN LEISHMANIASIS;

EID: 84989812003     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005852     Document Type: Article

References (68)

1. World Health OrganizationControl of the leishmaniases. World Health Organ Tech Rep Ser. 2010(949). 21485694
2. Fischer D, Moeller P, Thomas SM, Naucke TJ, Beierkuhnlein C, Combining climatic projections and dispersal ability: a method for estimating the responses of sandfly vector species to climate change. PLoS Negl Trop Dis. 2011;5(11):e1407. doi: 10.1371/journal.pntd.000140722140590
3. Ready PD, Leishmaniasis emergence in Europe. Euro Surveill. 2010;15(10):19505. 20403308
4. Gonzalez C, Wang O, Strutz SE, Gonzalez-Salazar C, Sanchez-Cordero V, Sarkar S, Climate change and risk of leishmaniasis in north america: predictions from ecological niche models of vector and reservoir species. PLoS Negl Trop Dis. 2010;4(1):e585. doi: 10.1371/journal.pntd.000058520098495
5. Hartley MA, Drexler S, Ronet C, Beverley SM, Fasel N, The immunological, environmental, and phylogenetic perpetrators of metastatic leishmaniasis. Trends Parasitol. 2014; doi: 10.1016/j.pt.2014.05.006
6. Goto H, Lauletta Lindoso JA, Cutaneous and mucocutaneous leishmaniasis. Infect Dis Clin North Am. 2012;26(2):293–307. doi: 10.1016/j.idc.2012.03.00122632640
7. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671. doi: 10.1371/journal.pone.003567122693548
8. Stuart KD, Weeks R, Guilbride L, Myler PJ, Molecular organization of Leishmania RNA virus 1. Proc Natl Acad Sci U S A. 1992;89(18):8596–600. 1382295
9. Tarr PI, Aline RF, Jr.Smiley BL, Scholler J, Keithly J, Stuart K, LR1: a candidate RNA virus of Leishmania. Proc Natl Acad Sci U S A. 1988;85(24):9572–5. 3200841
10. Zangger H, Hailu A, Desponds C, Lye LF, Akopyants NS, Dobson DE, et al. Leishmania aethiopica field isolates bearing an endosymbiontic dsRNA virus induce pro-inflammatory cytokine response. PLoS Negl Trop Dis. 2014;8(4):e2836. doi: 10.1371/journal.pntd.000283624762979
11. Zangger H, Ronet C, Desponds C, Kuhlmann FM, Robinson J, Hartley MA, et al. Detection of Leishmania RNA virus in Leishmania parasites. PLoS Negl Trop Dis. 2013;7(1):e2006. doi: 10.1371/journal.pntd.000200623326619
12. Ives A, Ronet C, Prevel F, Ruzzante G, Fuertes-Marraco S, Schutz F, et al. Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis. Science. 2011;331(6018):775–8. doi: 10.1126/science.119932621311023
13. Bourreau E, Ginouves M, Prevot G, Hartley MA, Gangneux JP, Robert-Gangneux F, et al. Presence of Leishmania RNA Virus 1 in Leishmania guyanensis Increases the Risk of First-Line Treatment Failure and Symptomatic Relapse. J Infect Dis. 2016;213(1):105–11. Epub 2015/07/01. doi: 10.1093/infdis/jiv35526123564
14. Adaui V, Lye LF, Akopyants NS, Zimic M, Llanos-Cuentas A, Garcia L, et al. Association of the Endobiont Double-Stranded RNA Virus LRV1 With Treatment Failure for Human Leishmaniasis Caused by Leishmania braziliensis in Peru and Bolivia. J Infect Dis. 2016;213(1):112–21. Epub 2015/07/01. doi: 10.1093/infdis/jiv35426123565
15. Cantanhede LM, da Silva Junior CF, Ito MM, Felipin KP, Nicolete R, Salcedo JM, et al. Further Evidence of an Association between the Presence of Leishmania RNA Virus 1 and the Mucosal Manifestations in Tegumentary Leishmaniasis Patients. PLoS Negl Trop Dis. 2015;9(9):e0004079. Epub 2015/09/16. doi: 10.1371/journal.pntd.000407926372217
16. Ives A, Masina S, Castiglioni P, Prevel F, Revaz-Breton M, Hartley MA, et al. MyD88 and TLR9 Dependent Immune Responses Mediate Resistance to Leishmania guyanensis Infections, Irrespective of Leishmania RNA Virus Burden. PLoS One. 2014;9(5):e96766. doi: 10.1371/journal.pone.009676624801628
17. Locksley RM, Heinzel FP, Holaday BJ, Mutha SS, Reiner SL, Sadick MD, Induction of Th1 and Th2 CD4+ subsets during murine Leishmania major infection. Res Immunol. 1991;142(1):28–32. 1829257
18. Louis JA, Conceicao-Silva F, Himmelrich H, Tacchini-Cottier F, Launois P, Anti-leishmania effector functions of CD4+ Th1 cells and early events instructing Th2 cell development and susceptibility to Leishmania major in BALB/c mice. Adv Exp Med Biol. 1998;452:53–60. 9889959
19. Alexander J, Bryson K, T helper (h)1/Th2 and Leishmania: paradox rather than paradigm. Immunol Lett. 2005;99(1):17–23. 15894106
20. Alexander J, Brombacher F, T helper1/t helper2 cells and resistance/susceptibility to leishmania infection: is this paradigm still relevant?Front Immunol. 2012;3:80. doi: 10.3389/fimmu.2012.0008022566961
21. Hartley MA, Ronet C, Zangger H, Beverley SM, Fasel N, Leishmania RNA virus: when the host pays the toll. Front Cell Infect Microbiol. 2012;2:99. doi: 10.3389/fcimb.2012.0009922919688
22. Tacchini-Cottier F, Weinkopff T, Launois P, Does T Helper Differentiation Correlate with Resistance or Susceptibility to Infection with L. major? Some Insights From the Murine Model. Front Immunol. 2012;3:32. doi: 10.3389/fimmu.2012.0003222566916
23. Bedoya SK, Lam B, Lau K, Larkin J, 3rd. Th17 cells in immunity and autoimmunity. Clin Dev Immunol. 2013;2013:986789. doi: 10.1155/2013/98678924454481
24. Yang B, Kang H, Fung A, Zhao H, Wang T, Ma D, The Role of Interleukin 17 in Tumour Proliferation, Angiogenesis, and Metastasis. Mediators Inflamm. 2014;2014:623759. doi: 10.1155/2014/62375925110397
25. Kim JW, Kim YK, Hwang JA, Yoon HK, Ko YH, Han C, et al. Plasma Levels of IL-23 and IL-17 before and after Antidepressant Treatment in Patients with Major Depressive Disorder. Psychiatry Investig. 2013;10(3):294–9. doi: 10.4306/pi.2013.10.3.29424302954
26. Holm CK, Petersen CC, Hvid M, Petersen L, Paludan SR, Deleuran B, et al. TLR3 ligand polyinosinic:polycytidylic acid induces IL-17A and IL-21 synthesis in human Th cells. J Immunol. 2009;183(7):4422–31. doi: 10.4049/jimmunol.080431819748983
27. Lee SY, Yoon BY, Kim JI, Heo YM, Woo YJ, Park SH, et al. Interleukin-17 increases the expression of Toll-like receptor 3 via the STAT3 pathway in rheumatoid arthritis fibroblast-like synoviocytes. Immunology. 2014;141(3):353–61. doi: 10.1111/imm.1219624708416
28. Hsia BJ, Whitehead GS, Thomas SY, Nakano K, Gowdy KM, Aloor JJ, et al. Trif-dependent induction of Th17 immunity by lung dendritic cells. Mucosal Immunol. 2014; doi: 10.1038/mi.2014.56
29. Said A, Bock S, Muller G, Weindl G, Inflammatory conditions distinctively alter immunological functions of Langerhans-like cells and dendritic cells in vitro. Immunology. 2014; doi: 10.1111/imm.12363
30. He J, Lang G, Ding S, Li L, Pathological role of interleukin-17 in poly I:C-induced hepatitis. PLoS One. 2013;8(9):e73909. doi: 10.1371/journal.pone.007390924069246
31. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123–32. 16200070
32. Irmler IM, Gajda M, Brauer R, Exacerbation of antigen-induced arthritis in IFN-gamma-deficient mice as a result of unrestricted IL-17 response. J Immunol. 2007;179(9):6228–36. 17947698
33. Kelchtermans H, Billiau A, Matthys P, How interferon-gamma keeps autoimmune diseases in check. Trends Immunol. 2008;29(10):479–86. doi: 10.1016/j.it.2008.07.00218775671
34. Savarin C, Stohlman SA, Hinton DR, Ransohoff RM, Cua DJ, Bergmann CC, IFN-gamma protects from lethal IL-17 mediated viral encephalomyelitis independent of neutrophils. J Neuroinflammation. 2012;9:104. doi: 10.1186/1742-2094-9-10422642802
35. Huh JR, Leung MW, Huang P, Ryan DA, Krout MR, Malapaka RR, et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORgammat activity. Nature. 2011;472(7344):486–90. Epub 2011/03/29. doi: 10.1038/nature0997821441909
36. Coleman DT, Gray AL, Stephens CA, Scott ML, Cardelli JA, Repurposed drug screen identifies cardiac glycosides as inhibitors of TGF-beta-induced cancer-associated fibroblast differentiation. Oncotarget. 2016; doi: 10.18632/oncotarget.8609. Epub 2016/04/09.
37. Solt LA, Kumar N, Nuhant P, Wang Y, Lauer JL, Liu J, et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature. 2011;472(7344):491–4. doi: 10.1038/nature1007521499262
38. Parmentier L, Cusini A, Muller N, Zangger H, Hartley MA, Desponds C, et al. Severe Cutaneous Leishmaniasis in a Human Immunodeficiency Virus Patient Coinfected with Leishmania braziliensis and Its Endosymbiotic Virus. Am J Trop Med Hyg. 2016; doi: 10.4269/ajtmh.15-0803. Epub 2016/02/03.
39. de Oliveira Ramos Pereira L, Maretti-Mira AC, Rodrigues KM, Lima RB, de Oliveira-Neto MP, Cupolillo E, et al. Severity of tegumentary leishmaniasis is not exclusively associated with Leishmania RNA virus 1 infection in Brazil. Mem Inst Oswaldo Cruz. 2013;108(5):665–7. 23903986
40. Ginouves M, Simon S, Bourreau E, Lacoste V, Ronet C, Couppie P, et al. Prevalence and Distribution of Leishmania RNA Virus 1 in Leishmania Parasites from French Guiana. Am J Trop Med Hyg. 2016;94(1):102–6. Epub 2015/11/26. doi: 10.4269/ajtmh.15-041926598572
41. Pereira Lde O, Maretti-Mira AC, Rodrigues KM, Lima RB, Oliveira-Neto MP, Cupolillo E, et al. Severity of tegumentary leishmaniasis is not exclusively associated with Leishmania RNA virus 1 infection in Brazil. Mem Inst Oswaldo Cruz. 2013;108(5):665–7. Epub 2013/08/02. 23903986
42. O'Neal SE, Guimaraes LH, Machado PR, Alcantara L, Morgan DJ, Passos S, et al. Influence of helminth infections on the clinical course of and immune response to Leishmania braziliensis cutaneous leishmaniasis. J Infect Dis. 2007;195(1):142–8. Epub 2006/12/08. 17152018
43. Crosby EJ, Clark M, Novais FO, Wherry EJ, Scott P, Lymphocytic Choriomeningitis Virus Expands a Population of NKG2D+CD8+ T Cells That Exacerbates Disease in Mice Coinfected with Leishmania major. J Immunol. 2015;195(7):3301–10. Epub 2015/08/21. doi: 10.4049/jimmunol.150085526290604
44. Swihart K, Fruth U, Messmer N, Hug K, Behin R, Huang S, et al. Mice from a genetically resistant background lacking the interferon gamma receptor are susceptible to infection with Leishmania major but mount a polarized T helper cell 1-type CD4+ T cell response. J Exp Med. 1995;181(3):961–71. 7869054
45. Pinheiro RO, Rossi-Bergmann B, Interferon-gamma is required for the late but not early control of Leishmania amazonensis infection in C57Bl/6 mice. Mem Inst Oswaldo Cruz. 2007;102(1):79–82. 17294004
46. Bacellar O, Lessa H, Schriefer A, Machado P, Ribeiro de Jesus A, Dutra WO, et al. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun. 2002;70(12):6734–40. 12438348
47. Hartley MA, Kohl K, Ronet C, Fasel N, The therapeutic potential of immune cross-talk in leishmaniasis. Clin Microbiol Infect. 2013;19(2):119–30. doi: 10.1111/1469-0691.1209523398405
48. Lopez Kostka S, Dinges S, Griewank K, Iwakura Y, Udey MC, von Stebut E, IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice. J Immunol. 2009;182(5):3039–46. doi: 10.4049/jimmunol.071359819234200
49. Gonzalez-Lombana C, Gimblet C, Bacellar O, Oliveira WW, Passos S, Carvalho LP, et al. IL-17 mediates immunopathology in the absence of IL-10 following Leishmania major infection. PLoS Pathog. 2013;9(3):e1003243. doi: 10.1371/journal.ppat.100324323555256
50. Boaventura VS, Santos CS, Cardoso CR, de Andrade J, Dos Santos WL, Clarencio J, et al. Human mucosal leishmaniasis: neutrophils infiltrate areas of tissue damage that express high levels of Th17-related cytokines. Eur J Immunol. 2010;40(10):2830–6. doi: 10.1002/eji.20094011520812234
51. Xin L, Li Y, Soong L, Role of interleukin-1beta in activating the CD11c(high) CD45RB- dendritic cell subset and priming Leishmania amazonensis-specific CD4+ T cells in vitro and in vivo. Infect Immun. 2007;75(10):5018–26. 17682041
52. Vargas-Inchaustegui DA, Xin L, Soong L, Leishmania braziliensis infection induces dendritic cell activation, ISG15 transcription, and the generation of protective immune responses. J Immunol. 2008;180(11):7537–45. 18490754
53. Bourreau E, Ronet C, Darcissac E, Lise MC, Sainte Marie D, Clity E, et al. Intralesional regulatory T-cell suppressive function during human acute and chronic cutaneous leishmaniasis due to Leishmania guyanensis. Infect Immun. 2009;77(4):1465–74. doi: 10.1128/IAI.01398-0819168733
54. Wortmann GW, Aronson NE, Miller RS, Blazes D, Oster CN, Cutaneous leishmaniasis following local trauma: a clinical pearl. Clin Infect Dis. 2000;31(1):199–201. 10913426
55. Bertho AL, Santiago MA, Coutinho SG, An experimental model of the production of metastases in murine cutaneous leishmaniasis. J Parasitol. 1994;80(1):93–9. 8308664
56. Scheffter SM, Ro YT, Chung IK, Patterson JL, The complete sequence of Leishmania RNA virus LRV2-1, a virus of an Old World parasite strain. Virology. 1995;212(1):84–90. 7676652
57. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D, MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A. 2007;104(5):1604–9. 17242365
58. Escobar T, Yu CR, Muljo SA, Egwuagu CE, STAT3 activates miR-155 in Th17 cells and acts in concert to promote experimental autoimmune uveitis. Invest Ophthalmol Vis Sci. 2013;54(6):4017–25. doi: 10.1167/iovs.13-1193723674757
59. Yao R, Ma YL, Liang W, Li HH, Ma ZJ, Yu X, et al. MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1. PLoS One. 2012;7(10):e46082. doi: 10.1371/journal.pone.004608223091595
60. Hu R, Huffaker TB, Kagele DA, Runtsch MC, Bake E, Chaudhuri AA, et al. MicroRNA-155 confers encephalogenic potential to Th17 cells by promoting effector gene expression. J Immunol. 2013;190(12):5972–80. doi: 10.4049/jimmunol.130035123686497
61. Gollob KJ, Antonelli LR, Faria DR, Keesen TS, Dutra WO, Immunoregulatory mechanisms and CD4-CD8- (double negative) T cell subpopulations in human cutaneous leishmaniasis: a balancing act between protection and pathology. Int Immunopharmacol. 2008;8(10):1338–43. doi: 10.1016/j.intimp.2008.03.01618687296
62. Bottrel RL, Dutra WO, Martins FA, Gontijo B, Carvalho E, Barral-Netto M, et al. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis. Infect Immun. 2001;69(5):3232–9. 11292745
63. Wang HX, Chu S, Li J, Lai WN, Wang HX, Wu XJ, et al. Increased IL-17 and IL-21 producing TCRalphabeta+CD4-CD8- T cells in Chinese systemic lupus erythematosus patients. Lupus. 2014;23(7):643–54. doi: 10.1177/096120331452446724554709
64. Rotureau B, Ravel C, Couppie P, Pratlong F, Nacher M, Dedet JP, et al. Use of PCR-restriction fragment length polymorphism analysis to identify the main new world Leishmania species and analyze their taxonomic properties and polymorphism by application of the assay to clinical samples. J Clin Microbiol. 2006;44(2):459–67. Epub 2006/02/04. 16455899
65. Lye LF, Owens K, Shi H, Murta SM, Vieira AC, Turco SJ, et al. Retention and loss of RNA interference pathways in trypanosomatid protozoans. PLoS Pathog. 2010;6(10):e1001161. doi: 10.1371/journal.ppat.100116121060810
66. Ro YT, Scheffter SM, Patterson JL, Hygromycin B resistance mediates elimination of Leishmania virus from persistently infected parasites. J Virol. 1997;71(12):8991–8. 9371555
67. Bourreau E, Prevot G, Gardon J, Pradinaud R, Launois P, High intralesional interleukin-10 messenger RNA expression in localized cutaneous leishmaniasis is associated with unresponsiveness to treatment. J Infect Dis. 2001;184(12):1628–30. 11740743
68. Nakae S, Komiyama Y, Nambu A, Sudo K, Iwase M, Homma I, et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity. 2002;17(3):375–87. 12354389